OrphAI Therapeutics Announces Oral Presentation and Posters at the 22nd Annual NEALS Conference

GUILFORD, Conn., Oct. 02, 2023 (GLOBE NEWSWIRE) — OrphAI Therapeutics Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today data presentations at the 22^nd Annual NEALS (Northeast ALS Consortium) meeting being held October 4 – 6, 2023 in Clearwater Florida.

Oral Presentation:

October 5, 2023, 11:10 a.m. ET

• Title: Results of the Phase 2a clinical trial of LAM-002A (apilimod dimesylate) in C9orf72 ALS
  Presenters: Dr. Suma Babu, Sean M. Healey Center for ALS at MGHl; Peter Young, Ph.D. Chief Scientific Officer, OrphAI Therapeutics.
  Location: Opal Ballroom

Poster Presentations:

• Title: AIT-101 Improves Functional Deficits in a Human TDP-43 Animal Model of ALS
  Presenter: Peter Young, Ph.D., Chief Scientific Officer, OrphAI Therapeutics
  Location and Time: Poster Session 1, Abstract:4, October 4, 2023, 5:15p – 7:15p ET

• Title: Results of a double blind, placebo-controlled clinical trial of AIT-101 (LAM-002A) in C9ORF72 ALS- A biomarker driven Phase 2a clinical trial targeting PIKfyve inhibition
  Presenter: Dr. Suma Babu, Sean M. Healey Center for ALS at MGH
  Location and Time: Poster Session 2, Abstract:136, October 5, 2023, 4:30p – 6:30p ET

About OrphAI Therapeutics

OrphAI Therapeutics’ mission is to transform the lives of patients with rare diseases. The company is currently developing three investigational therapies across multiple orphan indications: AIT-101, a first-in-class PIKfyve inhibitor, which recently completed a Phase 2a clinical trial in amyotrophic lateral sclerosis (ALS); LAM-001, a proprietary inhaled form of rapamycin, currently in Phase 2 for bronchiolitis obliterans syndrome (BOS) and pulmonary arterial hypertension (PAH); and AIT-102, a proprietary analogue of mithramycin, in preclinical development for the treatment of SWI/SNF mutated or dysregulated tumors. To learn more, please visit: OrphAI-Therapeutics.com

CONTACT: MEDIA CONTACT:
info@orphai-therapeutics.com

• Author
• Recent Posts

GlobeNewswire

GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Latest posts by GlobeNewswire (see all)

• Milled Carbon Fiber Market worth $302 million by 2029, at a CAGR of 10.8%, says MarketsandMarkets™ - June 5, 2025
• Logan Ridge Announces Change of Date to the Special Meeting of Stockholders to Allow Additional Time for Stockholders to Vote “FOR” the Merger Proposal - June 5, 2025
• Administrator Loeffler Applauds House Passage of“Save SBA from Sanctuary Cities Act” - June 5, 2025